Project Grant R01AR087085
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1.85 million Project Grant to the University of California, San Diego to investigate the role of lysine acetylation in skeletal muscle contractile function. The award, announced September 15, 2025, with completion targeted for August 31, 2028, will deliver research findings on how post-translational modifications of contractile proteins regulate skeletal muscle force...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Pennsylvania a $719,758 Project Grant on July 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of nuclear myotubularin (MTM1) in muscle development and X-linked myotubular myopathy (XLMTM). The research will be conducted through June 30, 2030, with the goal of understanding how MTM1 gene...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $554,797 project grant to The University of Kentucky Research Foundation, effective September 1, 2025, through May 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This project grant funds basic science research to define the rate of myonuclear turnover in adult skeletal muscle, identify mechanisms by which myonuclei are...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Maine a Project Grant totaling $471,513 (Award Date: September 5, 2025; Completion Date: August 31, 2030) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, titled "Tissue-Specific Roles for Muscle-Matrix Adhesion in Neuromuscular Development and Homeostasis," investigates the fundamental mechanisms...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Van Andel Research Institute (VAI) $1,622,775 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of mitochondrial oxidative metabolism in muscle satellite cell fate and function. The three-year project, running from September 1, 2025 through August 31, 2028, will generate research products including mechanistic...
- Federal Grant Award Summary Myogene Bio LLC received a $499,300 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded September 1, 2025, with completion targeted for July 31, 2028. The award supports the optimization of manufacturing processes and analytical testing protocols for a dual adeno-associated virus (AAV) vector gene editing therapy targeting...
- Federal Project Grant Award Summary The University of Florida received a $1.199 million Project Grant award dated September 15, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, extending through August 31, 2030, will deliver magnetic resonance (MR) research services focused on assessing the effects of neuronal nitric oxide synthase mu (nNOS) on...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $351,000 Project Grant to The Washington University, Office of Sponsored Research Services, effective September 1, 2025, through July 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds a comprehensive research investigation into the role of alternative splicing in facioscapulohumeral muscular dystrophy (FSHD)...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $540,712 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 1, 2025, through August 31, 2030. This award supports the development of an improved Adeno-Associated Virus (AAV) gene therapy for Pompe Disease, an inherited lysosomal storage...
- Federal Project Grant Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant totaling $3,056,688 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The three-year award, effective September 1, 2025, through August 31, 2028, funds fundamental research to elucidate the molecular mechanisms underlying skeletal muscle...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $614,390 Project Grant (CFDA 93.846) to the University of Georgia Research Foundation, Inc., with an award date of May 1, 2026, and completion date of April 30, 2031. This research project will investigate the molecular mechanisms of human myogenesis, specifically focusing on the CHAMP1 gene's role in CHAMP1 Syndrome, a severe developmental disorder characterized by muscle weakness and hypotonia. The research will deliver comprehensive molecular and functional analyses of CHAMP1's role in both embryonic and adult muscle development through tissue- and stage-specific mouse models, spatial transcriptomics analyses, and patient cell studies. The project will produce detailed scientific outputs including characterization of CHAMP1's biochemical mechanisms of action, particularly its function as a MyoD co-factor regulating myomaker expression through zinc finger motifs and protein complex interactions. Deliverables will encompass RNA sequencing data, chromatin immunoprecipitation data, protein interaction analyses, and structural protein modeling using AlphaFold3. Additionally, the project will establish new animal models and identify molecular targets for studying and treating muscle symptoms in CHAMP1 Syndrome, providing critical mechanistic insights into how CHAMP1 mutations cause fusion myopathy and advancing therapeutic development opportunities in musculoskeletal disease research.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $614.4k | 5/1/26 |